Anebulo Pharmaceuticals Book Value Per Share vs. Shares Outstanding
| ANEB Stock | USD 1.57 0.01 0.64% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 0.14764514 | Current Value 0.14 | Quarterly Volatility 0.28729965 |
For Anebulo Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Anebulo Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Anebulo Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Anebulo Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Anebulo Pharmaceuticals over time as well as its relative position and ranking within its peers.
Anebulo |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Return On Assets (0.66) | Return On Equity (1.14) |
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Anebulo Pharmaceuticals Shares Outstanding vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Anebulo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Anebulo Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Anebulo Pharmaceuticals is rated below average in book value per share category among its peers. It is rated below average in shares outstanding category among its peers creating about 176,416,327 of Shares Outstanding per Book Value Per Share. At present, Anebulo Pharmaceuticals' Book Value Per Share is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Anebulo Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Anebulo Shares Outstanding vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Anebulo Pharmaceuticals |
| = | 0.15 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Anebulo Pharmaceuticals |
| = | 25.93 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Anebulo Shares Outstanding Comparison
Anebulo Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Anebulo Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Anebulo Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Anebulo Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Anebulo Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Anebulo Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Interest Income | 249 K | 261.5 K | |
| Operating Income | -8.3 M | -8.7 M | |
| Income Before Tax | -8.2 M | -8.6 M | |
| Total Other Income Expense Net | 107.1 K | 112.4 K | |
| Net Loss | -10.6 M | -10 M | |
| Net Loss | -8.2 M | -8.6 M | |
| Income Tax Expense | -93.8 K | -89.1 K | |
| Net Interest Income | 97.8 K | 94.9 K | |
| Net Loss | -8.2 M | -8.6 M | |
| Change To Netincome | 1 M | 1.1 M | |
| Net Loss | (0.32) | (0.33) | |
| Income Quality | 0.99 | 0.58 | |
| Net Income Per E B T | 1.15 | 1.10 |
Anebulo Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Anebulo Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Anebulo Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Anebulo Pharmaceuticals' important profitability drivers and their relationship over time.
Use Anebulo Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anebulo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anebulo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Anebulo Pharmaceuticals Pair Trading
Anebulo Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Anebulo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anebulo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anebulo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anebulo Pharmaceuticals to buy it.
The correlation of Anebulo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anebulo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anebulo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anebulo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Anebulo Pharmaceuticals position
In addition to having Anebulo Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cleaning Thematic Idea Now
Cleaning
Compnanies producing and distributing cleaning products, supplies, and accessories. The Cleaning theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cleaning Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
To fully project Anebulo Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Anebulo Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Anebulo Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.